Article | September 30, 2019

Developing A New Biologic Drug: Regulatory Challenges And Considerations

Source: Cytiva

By Parrish Galliher and Brian Hubbard

Regulatory Concerns For Facilities Of The Future:  Does Flexibility Come With A Cost?

Regulatory challenges and considerations when bringing a new biologic to market

The journey from research lab to market is a long one, and most drug candidates do not make it. For those that do progress to market, there are many regulatory milestones and hurdles. As in other aspects of drug development, up-front planning can prevent headaches down the road. One of the key decisions is knowing when your team is short on regulatory experience and expertise, and when to call on a consultant or hire an expert to fill the gap. Your regulatory investigator can also be an excellent resource, who can share valuable knowledge and advice. Meet with them early, and cultivate a good relationship.

Phase I clinical trials are first-in-human trials on healthy subjects to determine drug safety. As you complete pre-clinical trials and plan to move to clinical Phase 1 trials, you must plan for compliance with a strict level of regulatory requirements as part of these efforts.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: